The VC is funded mainly via Rigmora Biotech Investor One and Rigmora Biotech Investor Two, according to a June 27 press ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

Pfizer will pay a $0.43 quarterly dividend on September 2, 2025, maintaining its 347-quarter streak of shareholder payouts.

The liver fibrosis market is entering a transformative phase, driven by greater awareness, improved diagnostic ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

Detailed price information for Rapt Therapeutics Inc (RAPT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report)’s stock price gapped up before the market opened on Friday after an insider bought additional shares in the company.

Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price boosted by HC Wainwright from $72.00 to $75.00 in a report published on Monday morning,Benzinga reports.

Akero Therapeutics' chief scientific officer sells $1.06 million in stock ...

Akero Therapeutics also reported preliminary topline results from its Phase 2b SYMMETRY study, which showed a statistically significant reversal in fibrosis for patients treated with EFX.

Akero Therapeutics ( (AKRO) ) has released its Q3 earnings. Here is a breakdown of the information Akero Therapeutics presented to its investors. Akero Therapeutics is a clinical-stage ...